Cipla's Strategic Acquisition of Inzpera Healthscience

Cipla has announced a definitive agreement to acquire Inzpera Healthscience, a Mumbai-based firm specializing in pediatric pharmaceutical and wellness products, for approximately Rs 111 crore. The acquisition aims to integrate Inzpera's product portfolio with Cipla's distribution strength, enhancing growth and scalability prospects.

Pharmaceutical giant Cipla has announced it will acquire the entirety of Inzpera Healthscience, a Mumbai-based company specializing in pediatric pharmaceutical and wellness products, for around Rs 111 crore.

Cipla revealed in a regulatory filing that it has signed definitive agreements to gain full control of Inzpera. This acquisition is set to enhance Cipla's product range and market penetration, particularly in the pediatric segment.

Inzpera, established in 2016, is valued at approximately Rs 120 crore. The deal's structure includes equity shares and non-convertible redeemable preference shares, with Cipla accounting for necessary working capital adjustments.

(With inputs from agencies.)